CENTRAL ASIAN JOURNAL OF NEPHROLOGY
Short Communication
Sep 06, 2025 15 6

Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan

Saltanat Tuganbekova 1 2 * ,
Gulzhan Yertlessova 1 2,
Kairat Kabulbayev 3,
Ainur Botabayeva 4,
Duman Turebekov 2,
Aigul Karabayeva 5,
Sholpan Kanafina 1 2,
Galiya Shaimardanova 6,
Olimkhon Sharapov 7 8,
Fariz Babayev 9,
Miranda Tsilosani 10 11,
Kirill Komissarov 12 13,
Irma Tchokhonelidze 14,
Abduzhappar Gaipov 15
1 Public Foundation "National Kidney Fund of the Republic of Kazakhstan", Astana, Kazakhstan2 Department of Internal Medicine, Astana Medical University, Astana, Kazakhstan3 Department of Nephrology, Kazakh National Medical University named after S.D. Asfendiyarov, Almaty, Kazakhstan4 Department of Internal Medicine and Rheumatology, Semey Medical University, Semey, Kazakhstan5 Department of General Medical Practice, Kazakh-Russian Medical University, Almaty, Kazakhstan6 Department of Pathomorphology, National Scientific Medical Center, Astana, Kazakhstan7 Department of Adult and Pediatric Nephrology, Republican Specialized Scientific Practical Medical Center of Nephrology and Kidney Transplantation, Tashkent, Uzbekistan8 Department of Nephrology and Hemodialysis, Tashkent State Medical University, Tashkent, Uzbekistan 9 Republican Clinic Hospital of Urology named by acad. M.Javad-Zade, Baku, Azerbaijan 10 Department of Pathology, Enmedic - Vazha Iverieli Endocrinology Metabology Dietology Centre, Tbilisi, Georgia11 Faculty of Medicine, Caucasus International University, Tbilisi, Georgia12 Department of Nephrology, Renal Replacement Therapy and Kidney Transplantation, Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology, Minsk, Republic of Belarus13 Belarusian State Medical University, Minsk, Republic of Belarus14 Department of Nephrology, Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tibilisi, Georgia15 Department of Medicine, School of Medicine, Nazarbayev University, Astana, Kazakhstan* Corresponding Author
Central Asian Journal of Nephrology, 1(1), 2025, cajn005, https://doi.org/10.63946/cajn/16888
Online publication date: Sep 01, 2025
Publication date: Sep 06, 2025
Full Text (PDF)

ABSTRACT

The advent of targeted complement inhibitors represents a paradigm shift in managing complement-mediated nephropathies. Integrating these therapies into healthcare systems, particularly in resource-variable settings, requires strategic planning.
A national council of experts was convened in October 2024 with the purpose of obtaining a clinical expert opinion to develop practical recommendations for improving the organization and optimization of medical care for patients with C3 glomerulopathy (C3G) and IgA nephropathy (IgAN) in Kazakhstan.
The council identified critical systemic gaps, including inconsistent use of renal biopsy, lack of specialized nephropathology, absence of treatment algorithms, and fragmented patient care. A consensus was reached on key recommendations for a new national clinical protocol. These include mandating pathological confirmation, creating detailed treatment and monitoring algorithms, establishing a national registry and coordination center, and investing in specialized training for healthcare professionals.
The systematic framework proposed by the council provides an actionable roadmap to overcome barriers to care. This model ensures equitable patient access to novel therapies and may serve as a blueprint for other nations navigating the integration of advanced treatments into clinical practice.

KEYWORDS

C3 Glomerulopathy IgA Nephropathy Complement System Targeted Therapy Ip-tacopan Clinical Protocol Kazakhstan Healthcare Policy

CITATION (Vancouver)

Tuganbekova S, Yertlessova G, Kabulbayev K, Botabayeva A, Turebekov D, Karabayeva A, et al. Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan. Central Asian Journal of Nephrology. 2025;1(1):cajn005. https://doi.org/10.63946/cajn/16888
APA
Tuganbekova, S., Yertlessova, G., Kabulbayev, K., Botabayeva, A., Turebekov, D., Karabayeva, A., Kanafina, S., Shaimardanova, G., Sharapov, O., Babayev, F., Tsilosani, M., Komissarov, K., Tchokhonelidze, I., & Gaipov, A. (2025). Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan. Central Asian Journal of Nephrology, 1(1), cajn005. https://doi.org/10.63946/cajn/16888
Harvard
Tuganbekova, S., Yertlessova, G., Kabulbayev, K., Botabayeva, A., Turebekov, D., Karabayeva, A., . . . Gaipov, A. (2025). Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan. Central Asian Journal of Nephrology, 1(1), cajn005. https://doi.org/10.63946/cajn/16888
AMA
Tuganbekova S, Yertlessova G, Kabulbayev K, et al. Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan. Central Asian Journal of Nephrology. 2025;1(1), cajn005. https://doi.org/10.63946/cajn/16888
Chicago
Tuganbekova, Saltanat, Gulzhan Yertlessova, Kairat Kabulbayev, Ainur Botabayeva, Duman Turebekov, Aigul Karabayeva, Sholpan Kanafina, Galiya Shaimardanova, Olimkhon Sharapov, Fariz Babayev, Miranda Tsilosani, Kirill Komissarov, Irma Tchokhonelidze, and Abduzhappar Gaipov. "Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan". Central Asian Journal of Nephrology 2025 1 no. 1 (2025): cajn005. https://doi.org/10.63946/cajn/16888
MLA
Tuganbekova, Saltanat et al. "Integrating Novel Complement Inhibitors into Clinical Practice: A National Call to Action for C3 Glomerulopathy and IgA Nephropathy in Kazakhstan". Central Asian Journal of Nephrology, vol. 1, no. 1, 2025, cajn005. https://doi.org/10.63946/cajn/16888

REFERENCES

  1. Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, et al. C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15(3):129-143. DOI: 10.1038/s41581-019-0119-6
  2. Boyd JK, Cheung CK, Molyneux K, Feehally J, Barratt J. An update on the pathogenesis and treatment of IgA nephropathy. Kidney Int. 2012;81(9):833-843. DOI: 10.1038/ki.2011.501
  3. Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, et al. Targeting complement in IgA nephropathy: the evolving landscape. Nephrol Dial Transplant. 2024;39(5):725-735. DOI: 10.1093/ndt/gfad228
  4. Bomback AS, Kavanagh D, Vivarelli M, Meier M, Wang Y, Webb NJA, et al. Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy: study design of the APPEAR-C3G trial. Kidney Int Rep. 2022;7(10):2150-2159. DOI: 10.1016/j.ekir.2022.07.004
  5. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. DOI: 10.1016/j.kint.2021.05.021

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.